In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced. Currently CEO of Roche Pharmaceuticals since ...

Merck & Co. (NYSE:MRK) and Gilead Sciences Inc. (NYSE:GILD) are two pharmaceutical heavyweights whose stocks tell very ...

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.

and he says the potential scalability of Gilead subsidiary Kite Pharma's cell therapy business is impressive. He is confident in Gilead's ability to maintain a leadership position in the $40 ...

Zacks Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on ...

Van Buren covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Moderna, and BridgeBio Pharma. In another report released today, Bank of America Securities also reiterated a ...

Gilead will pay Genesis $35 million for three targets. There could also be further payments if more targets are identified, along with milestone payments. Genesis previously collaborated with ...